From the Research
Antibodies like rituximab are not the primary treatment option for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), but may be considered as alternative treatments when first-line therapies fail, as suggested by recent studies 1, 2. The primary treatment options for CIDP include plasma exchange, intravenous immunoglobulin therapy, and corticosteroid administration, as outlined in the most recent study 3.
- These treatments are effective as induction and maintenance therapies for CIDP.
- Repeat intravenous or subcutaneous immunoglobulin infusion therapy has been introduced as a maintenance treatment, offering additional benefits such as reduced frequency of systemic adverse events and increased patient independence 4.
- Immunosuppressants or rituximab may be used in special cases, but their use requires careful consideration of the risks and benefits, as well as individualization of treatment based on disease behavior and patient response 1, 2.
- Treatment response should be monitored through clinical assessment of muscle strength, sensory function, and electrophysiological studies, with adjustments made to the treatment plan as needed to optimize outcomes and minimize adverse effects 2.
- The use of antibodies like rituximab in CIDP is supported by studies demonstrating their efficacy in reducing antibody production and immune system dysregulation, although they are not FDA-approved specifically for this indication 1, 2.